Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least isoniazid and rifampicin), has a relevant epidemiological impact, with 480, 000 cases and 190,000 deaths notified in 2014; 10% of them meet the criteria for extensively drug-resistant (XDR)-TB [MDR-TB with additional resistance to any fluoroquinolone, and to at least one injectable second-line drugs (SLDs)] (capreomycin, kanamycin or amikacin) (1,2).

[1]  D. Jeon.  WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea , 2017, Tuberculosis and respiratory diseases.

[2]  Alimuddin Zumla,et al.  Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis , 2016, European Respiratory Journal.

[3]  A. Diacon,et al.  β-Lactams against Tuberculosis--New Trick for an Old Dog? , 2016, The New England journal of medicine.

[4]  A. Matteelli,et al.  Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges , 2016, European Respiratory Journal.

[5]  Simon Tiberi,et al.  First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline , 2016, European Respiratory Journal.

[6]  Alimuddin Zumla,et al.  Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Alimuddin Zumla,et al.  Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB , 2016, European Respiratory Journal.

[8]  Alimuddin Zumla,et al.  Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB , 2016, European Respiratory Journal.

[9]  E. Pontali,et al.  Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence , 2016, European Respiratory Journal.

[10]  G. Sotgiu,et al.  Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience , 2015, European Respiratory Journal.

[11]  J. Caminero,et al.  Classification of antituberculosis drugs: a new proposal based on the most recent evidence , 2015, European Respiratory Journal.

[12]  Francesco Castelli,et al.  Towards tuberculosis elimination: an action framework for low-incidence countries , 2015, European Respiratory Journal.

[13]  D. van Soolingen,et al.  Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[14]  L. Geiter,et al.  Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid , 2015, European Respiratory Journal.

[15]  H. Mauch,et al.  Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains , 2015, European Respiratory Journal.

[16]  E. Pontali,et al.  Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios , 2015, European Respiratory Journal.

[17]  J. Gu,et al.  Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China , 2016, European Respiratory Journal.

[18]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[19]  F. Blasi,et al.  ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use , 2014, European Respiratory Journal.

[20]  A. Spanevello,et al.  Tuberculosis elimination: theory and practice in Europe , 2014, European Respiratory Journal.

[21]  G. Sotgiu,et al.  Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? , 2013, European Respiratory Journal.

[22]  Simon Tiberi,et al.  Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use , 2013, European Respiratory Journal.

[23]  C. Leung,et al.  WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis , 2013, Antimicrobial Agents and Chemotherapy.

[24]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[25]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[26]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[27]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[28]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[29]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[30]  G. Sotgiu,et al.  On linezolid efficacy and tolerability , 2012, European Respiratory Journal.

[31]  N. Ford,et al.  Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  G. Sotgiu,et al.  Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis , 2011, European Respiratory Journal.

[33]  M. D. Granado,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[34]  Alimuddin Zumla,et al.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. , 2010, The Lancet. Infectious diseases.

[35]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[36]  J. Fitzgerald,et al.  Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.